


Attorney Docket Number O 98411 US

REMARKS

In reply to the Office Action of August 13, 2003, Applicants have again cancelled claim 9. In fact, claim 9 was cancelled by the Amendment filed February 4, 2003.

Claims 1-6 and 10 are now the claims remaining in this application, all of which have been allowed. Immediate issuance of a Notice of Allowance is respectfully requested.

Respectfully Submitted,


William M. Blackstone
Attorney for Applicants
Registration No. 29,772

Akzo Nobel Patent Department
Intervet Inc.
405 State Street
P.O. Box 318
Millsboro, DE 19966
Tel: (410) 464-0581
Sec: (302) 933-4027
Fax: (302) 934-4305

Attorney Docket Number 0 98411 US

aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy or halogen; and


R^3 is selected from (1-8C)alkyl and (3-8C)cycloalkyl, which are unsubstituted or substituted with (3-6C)cycloalkyl or (1-6C)alkoxy, and from (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen and from Het-(1-6C)alkyl.

5. (Previously presented) The serine protease inhibitor according to claim 4, wherein

J is $-CH_2COO(1-6C)alkyl$, (3-8C)cycloalkyl, $-SO_2-10\text{-camphor}$, $-CH_2CONHphenyl$ or $-CH_2CONH(3-8C)cycloalkyl$;

Z is D-cyclohexylalaninyl, D-phenylalaninyl, D-diphenylalaninyl or glutamyl, or an (1-6C)alkylester thereof; and

E is the fragment



6. (Previously presented) A pharmaceutical composition comprising the serine protease inhibitor of claim 1 and at least one pharmaceutically suitable auxillary.

Claims 7 - 9 Cancelled)

10. (Previously presented) A method of effecting serine protease inhibition in a mammal, comprising administering an effective amount of a serine protease inhibitor according to claim 1.